Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Goodwill Amortization of Goodwill Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased

Daily Values

Growth Metrics

Angiodynamics (ANGO) Divestments (2023 - 2024)

Angiodynamics' Divestments history spans 2 years, with the latest figure at $34.5 million for Q1 2024.

For Q1 2024, Divestments changed N/A year-over-year to $34.5 million; the TTM value through Nov 2024 reached $34.5 million, down 65.5%, while the annual FY2024 figure was $134.5 million, N/A changed from the prior year.
Divestments reached $34.5 million in Q1 2024 per ANGO's latest filing, down from $100.0 million in the prior quarter.
In the past five years, Divestments ranged from a high of $100.0 million in Q3 2023 to a low of $34.5 million in Q1 2024.